Análisis económico del cociente de preeclampsia sFlt- 1/PlGF comparado con el estándar de atención en Uruguay

Poon L, Shennan A, Hyett J, Kapur A, Hadar E, Divakar H, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019;145(Supl 1):1-33. https://doi.org/10.1002/ijgo.12802

Rana S, Lemoine E, Granger J, Karumanchi S. Preeclampsia: Pathophysiology, challenges, and perspectives. Circ Res. 2019;124:1094-112. https://doi.org/10.1161/CIRCRESAHA.118.313276

Brown M, Magee L, Kenny L, Karumanchi S, McCarthy F, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018;72:24-43. https://doi.org/10.1161/HYPERTENSIONAHA.117.10803

Stevens W, Shih T, Incerti D, Ton T, Lee H, Peneva D, et al. Short-term costs of preeclampsia to the United States healthcare system. Am J Obstet Gynecol. 2017;217:237-48.e16. https://doi.org/10.1016/j.ajog.2017.04.032

Delahaije D, Smits L, Van Kuijk S, Peeters L, Duvekot J, Ganzevoort W, et al. Care-as-usual provided to formerly preeclamptic women in the Netherlands in the next pregnancy: Health care consumption, costs and maternal and child outcome. Eur J Obstet Gynecol Reprod Biol. 2014;179:240-5. https://doi.org/10.1016/j.ejogrb.2014.04.033

Hao J, Hassen D, Hao Q, Graham J, Paglia M, Brown J, et al. Maternal and infant health care costs related to preeclampsia. Obstet Gynecol. 2019;134:1227-33. https://doi.org/10.1097/AOG.0000000000003581

Ministerio de Salud, Uruguay. Estadísticas Vitales [Internet]; 2007. Disponible en: http://colo1.msp.gub.uy/redbin/RpWebEngine.exe/Portal?lang=esp

National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management [Internet]. Disponible en: https://www.nice.org.uk/guidance/NG133

Wagner L. Diagnosis and management of preeclampsia. Am Fam Physician. 2004;70:2317-24.

Stocks G. Preeclampsia: Pathophysiology, old and new strategies for management. Eur J Anaesthesiol. 2014;31:183-9. https://doi.org/10.1097/EJA.0000000000000044

Steegers E, Von Dadelszen P, Duvekot J, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376:631-44. https://doi.org/10.1016/S0140-6736(10)60279-6

Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia part 1: Current understanding of its pathophysiology. Nat Rev Nephrol. 2014;10:466-80. https://doi.org/10.1038/nrneph.2014.102

Saudan P, Brown M, Buddle M, Jones M. Does gestational hypertension become pre-eclampsia? Br J Obstet Gynaecol. 1998;105:1177-84. https://doi.org/10.1111/j.1471-0528.1998.tb09971.x

Bailey D, Walton S. Routine investigations might be useful in pre-eclampsia, but not in gestational hypertension. Aust N Z J Obstet Gynaecol. 2005;45:144-7. https://doi.org/10.1111/j.1479-828X.2005.00382.x

Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374:13-22. https://doi.org/10.1056/NEJMoa1414838

Hund M, Allegranza D, Schoedl M, Dilba P, Verhagen-Kamerbeek W, Stepan H. Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): Study protocol. BMC Pregnancy Childbirth. 2014;14:324. https://doi.org/10.1186/1471-2393-14-324

Ministerio de Desarrollo Social, Uruguay. Guías en salud sexual y reproductiva. Manual para la atención a la mujer en el proceso de embarazo, parto y puerperio [Internet]. Disponible en: https://www.gub.uy/ministerio-desarrollosocial/comunicacion/publicaciones/guias-salud-sexualreproductiva-manual-para-atencion-mujer-proceso.

Mutter W, Karumanchi S. Molecular mechanisms of preeclampsia. Microvasc Res. 2008;75:1-8. https://doi.org/10.1016/j.mvr.2007.04.009

Levine R, Lam C, Qian C, Yu K, Maynard S, Sachs B, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992-1005. https://doi.org/10.1056/NEJMoa055352

Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, et al. New gestational phase-specific cutoff values for the use of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014;63:346-52. https://doi.org/10.1161/HYPERTENSIONAHA.113.01787

Zhao M, Zhu Z, Liu C, Zhang Z. Dual-cutoff of sFlt-1/PlGF ratio in the stratification of preeclampsia: A systematic review and meta-analysis. Arch Gynecol Obstet. 2017;295:1079-87. https://doi.org/10.1007/s00404-017-4302-3

Agrawal S, Cerdeira A, Redman C, Vatish M. Metaanalysis and systematic review to assess the role of soluble Fms-like tyrosine kinase-1 and placenta growth factor ratio in prediction of preeclampsia: The SaPPPhirE study. Hypertension. 2018;71:306-16. https://doi.org/10.1161/HYPERTENSIONAHA.117.10182

Liu Y, Zhao Y, Yu A, Zhao B, Gao Y, Niu H. Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: A metaanalysis based on 20 studies. Arch Gynecol Obstet. 2015;292:507-18.https://doi.org/10.1007/s00404-015-3671-8

Stepan H, Herraiz I, Schlembach D, Verlohren S, Brennecke S, et al. Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: Implications for clinical practice. Ultrasound Obstet Gynecol. 2015;45:241-6. https://doi.org/10.1002/uog.14799

Córdoba S, Brenes G, Fonseca G. Algoritmo de manejo de los trastornos hipertensivos del embarazo utilizando la relación sFLt-1/PlGF Abordaje de los trastornos hipertensivos del embarazo con la relación sFLt-1/PlGF. Clin Investig Gineco. 2021;48. https://doi.org/10.1016/j.gine.2020.09.001

Schlembach D, Hund M, Schroer A, Wolf C. Economic assessment of the use of the sFlt-1/PlGF ratio test to predict preeclampsia in Germany. BMC Health Serv Res. 2018;18:603.https://doi.org/10.1186/s12913-018-3406-1

Frusca T, Gervasi M, Paolini D, Dionisi M, Ferre F, Cetin I. Budget impact analysis of sFlt-1/PlGF ratio as prediction test in Italian women with suspected preeclampsia. J Matern Fetal Neonatal Med. 2017;30:2166-73. https://doi.org/10.1080/14767058.2016.1242122

Hodel M, Blank PR, Marty P, Lapaire O. sFlt-1/PlGF Ratio as a predictive marker in women with suspected preeclampsia: An economic evaluation from a Swiss perspective. Dis Markers. 2019;2019:4096847. https://doi.org/10.1155/2019/4096847

AGO.uy. Consenso argentino-uruguayo sobre la utilidad del cociente de biomarcadores sFlt-1/ PIGF para preeclampsia en el 2do y 3er trimestre de embarazo [Internet]. Disponible en: https://ago.uy/separatas/consenso-argentino-uruguayo-sobrela-utilidad-del-cociente-de-biomarcadores-sflt-pigf-para-preeclampsia-en-el-2do-y-3er-trimestredeembarazo#attachmentsHeader.

Sullivan S, Mauskopf J, Augustovski F, Caro J, Lee K, Minchin M, et al. Budget impact analysis - Principles of good practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014;17:5-14. https://doi.org/10.1016/j.jval.2013.08.2291

Garay OU, Guiñazú GG, Basualdo N, Di Marco I, Zilberman J, Voto L. Economic Impact Analysis of Incorporation of Elecsys sFlt-1/PlGF Ratio Into Routine Practice for the Diagnosis and Follow-Up of Pregnant Women With Suspected Preeclampsia in Argentina. Value Health Reg Issues. 2023;34:1-8. https://doi.org/10.1016/j.vhri.2022.09.003

Husereau D, Drummond M, Augustovski F, De Bekker-Grob E, Briggs A, Carswell C, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: Updated reporting guidance for health economic evaluations. Value Health. 2022;25:3-9. https://doi.org/10.1016/j.jval.2021.11.1351

Mauskopf J, Sullivan S, Annemans L, Caro J, Mullins C, Nuijten M, et al. Principles of good practice for budget impact analysis: Report of the ISPOR Task Force on good research practices—budget impact analysis. Value Health. 2007;10:336-47. https://doi.org/10.1111/j.1524-4733.2007.00187.x

Banco Central del Uruguay. Cotización de monedas [Internet]. Disponible en: https://www.bcu.gub.uy/Estadisticas-e-Indicadores/Paginas/Cotizaciones.aspx

Observatorio del sistema de Salud del Uruguay [Internet]. Disponible en: http://www.observatoriosalud.org.uy.

Unidad Centralizada de Adquisiciones. Llamado No. 5/2016 contratación de servicios de CTI para pacientes de ASSE y otros organismos del sector público [Internet]. Disponible en: http://uca.mef.gub.uy/28241/13/areas/llamado-n%C2%BA-5_2016-contratacion-de-serviciosde-cti-para-pacientes-de-assey-otros-organismos-delsector-publico.html.

Unidad Centralizada de Adquisiciones. Llamado No. 9/2015- Suministro de estudios y procedimientos médicos [Internet]. Disponible en: https://www.mef.gub.uy/17154/13/areas/llamado-n%C2%BA-9_2015--suministro-de-estudios-y-procedimientos-medicos.html

Caldwell D, Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Int J Epidemiol. 2007;36(2)476-7. https://doi.org/10.1093/ije/dym062

Adamiak G. Methods for the economic evaluation of health care programmes, 3rd ed. J Epidemiol Community Health. 2006;60(9):822-23.

Chantraine F, Van Calsteren K, Devlieger R, Gruson D, Van Keirsbilck J, Dubon Garcia A, et al. Enhancing the value of the sFlt-1/PlGF ratio for the prediction of preeclampsia: Cost analysis from the Belgian healthcare payers' perspective. Pregnancy Hypertens. 2021;26:31-7. https://doi.org/10.1016/j.preghy.2021.08.113

Ontario Health (Quality). Placental growth factor (PLGf) - based biomarker testing to help diagnose pre-eclampsia in people with suspected pre-eclampsia: A health technology assessment. Ont Health Technol Assess Ser. 2023;23:1-146.

Figueira S, Wolf C, D'Innocenzo M, De Carvalho J, Barbosa M, Zlotnik E, et al. Economic evaluation of sFlt-1/PlGF ratio test in pre-eclampsia prediction and diagnosis in two Brazilian hospitals. Pregnancy Hypertens. 2018;13:30-6. https://doi.org/10.1016/j.preghy.2018.04.014

Myrhaug H, Reinar L, Stoinska A, Hval G, Movik E, Brurberg K, et al. Safety, clinical effectiveness, predictive accuracy and cost effectiveness of blood based tests for women with suspected preeclampsia: A health technology assessment 2020. Oslo: Norwegian Institute of Public Health. 2020.

Stepan H, Hund M, Dilba P, Sillman J, Schlembach D. Elecsys® and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: Are they comparable? Clin Chem Lab Med. 2019;57:1339-48. https://doi.org/10.1515/cclm-2018-1228

Lefèvre G, Hertig A, Guibourdenche J, Lévy P, Bailleul S, Drouin D, et al. Decision-making based on sFlt-1/PlGF ratios: Are immunoassay results interchangeable for diagnosis or prognosis of preeclampsia? Clin Chem Lab Med. 2020;59:e87-e89. https://doi.org/10.1515/cclm-2020-0084

Vatish M, Strunz T, Hund M, Allegranza D, Wolf C, Smare C, et al. sFlt-1/PlGF ratio test for pre-eclampsia: An economic assessment for the UK. Ultrasound Obstet Gynecol. 2016;48:765-71. https://doi.org/10.1002/uog.15997

Regitz V, Roos J, Bauersachs J, Blomstrom C, Cifkova R, De Bonis M, et al. ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39:3165-3241.

National Institute for Health and Care Excellence (NICE). PLGF-based testing to help diagnose suspected preterm pre-eclampsia. Diagnostics guidance [DG49] [Internet]. 2022. Disponible en: https://www.nice.org.uk/guidance/dg49

National Institute for Health and Care Excellence (NICE). Hypertension in Pregnancy: Diagnosis and management (National Institute for Health and Care Excellence). NICE guideline 133 [Internet]. 2019. Disponible en: https://www.nice.org.uk/guidance/ng133/resources/hypertension-in-pregnancy-diagnosis-andmanagementpdf-66141717671365

Stepan H, Kuse S, Klockenbusch W, Rath W, Schauf B, Walther T, et al. Diagnosis and treatment of hypertensive pregnancy disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013). Geburtshilfe Frauenheilkd. 75:900-14. https://doi.org/10.1055/s-0035-1557924

Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Hypertensive Schwangerschaftserkrankungen: Diagnostik und Therapie. Version 1.1. [Internet]. Disponible en: https://register.awmf.org/assets/guidelines/015-018l_S2k_Diagnostik_Therapie_hypertensiver_Schwangerschaftserkrankungen_2019-07.pdf